Avalide

Avalide is a brand name of hydrochlorothiazide/irbesartan, approved by the FDA in the following formulation(s):

AVALIDE (hydrochlorothiazide; irbesartan - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS
  
  Approval date: September 30, 1997
  
  Strength(s): 12.5MG;150MG ^[RLD]


• 
  Manufacturer: SANOFI AVENTIS
  
  Approval date: August 31, 1998
  
  Strength(s): 12.5MG;300MG
  

Has a generic version of Avalide been approved?

No. There is currently no therapeutically equivalent version of Avalide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avalide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
  Patent 5,270,317
  Issued: December 14, 1993
  Inventor(s): Bernhart; Claude & Breliere; Jean-Claude & Clement; Jacques & Nisato; Dino & Perreault; Pierre & Muneaux; Claude & Muneaux; Yvette
  Assignee(s): Elf Sanofi
  The invention relates to N-substituted heterocyclic derivatives and its salts. These derivatives have the formula ##STR1## in which the substituents are as defined in the specification. Application: Angiotensin II antagonists
  
  Patent expiration dates:
  
  
  • September 30, 2011
    
  
  
  
  • September 30, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 30, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing irbesartan
  Patent 5,994,348
  Issued: November 30, 1999
  Inventor(s): Ku; Cathy C. & Sprockel; Omar L. & Lang; Beth A. & Desai; Divyakant S.
  Assignee(s): Sanofi
  Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.
  
  Patent expiration dates:
  
  
  • June 7, 2015
    
  
  
  
  • June 7, 2015
    
    ✓ 
    Drug product
  
  
  
  • December 7, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 16, 2010 - USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
  
  

See also...

• Avalide Consumer Information (Drugs.com)
• Avalide Consumer Information (Wolters Kluwer)
• Avalide Consumer Information (Cerner Multum)
• Avalide Advanced Consumer Information (Micromedex)
• Irbesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and irbesartan Consumer Information (Cerner Multum)
• Irbesartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)